Company Active LTD

Company profile

Almac Discovery Limited

Partnering to Advance Human Health - Almac

Almac Group - Partnering to Advance Human Health. Providing a range of contract pharmaceutical development and manufacturing services globally.

CRN
NI046249
Founded
2003
Age
23

Overview

Legal name
ALMAC DISCOVERY LIMITED
Region
Northern Ireland
Registered address
ALMAC HOUSE
20 SEAGOE INDUSTRIAL ESTATE
CRAIGAVON
BT63 5QD
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

3 levels 2 ultimate controllers
1
Company Active LTD
Almac Discovery Limited
CRN NI046249
2
Direct controller Active LTD
Almac Group Limited
CRN NI041551
3
Intermediate controller Active PRIVATE-LIMITED-GUARANT-NSC-LIMITED-EXEMPTION
The Mcclay Foundation
CRN NI070062
4
Ultimate controller Active PRIVATE-LIMITED-GUARANT-NSC
5
Ultimate controller Active PRIVATE-LIMITED-GUARANT-NSC

Company events

Reference milestones and recent Companies House filing stream events.

5 events
30 Jun
2027

Accounts due

Accounts Due

Next accounts due date

28 Feb
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

14 Feb
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Sep
2025

Accounts filed

Accounts

Last accounts made up date

17 Apr
2003

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2018
Funded years
2018, 2021, 2024
Age at first award
15 years

Projects

2024 Collaborative R&D

Future Medicines Institute Application

1 Nov 2024 to 31 Oct 2029

Awarded
£5,385,495
Total cost £10,770,990

**The Northern Ireland Precision Biomarkers and Therapeutics Consortium (NIPBT)** is a partnership of Life and Health Science (LHS) companies and Academia, aligned to the strategies of both the Departments of Health and Economy of the NI devolved government to enhance health and wealth creation for NI citizens. Currently, NI has a significant presence in ...

2021 Study

Targeting Deubiquitinases to Treat Drug-Resistant Colorectal Cancer

1 Feb 2021 to 31 Dec 2023

Awarded
£0
Total cost £0

Colorectal cancer (CRC) has one of the highest Worldwide incidences and mortality rates (annually \>1.3M new cases and ~610,000 deaths). Hence, there is a critical need to develop new therapeutic approaches to treat this disease, particularly in its later stages where the mortality rates are worst. Moreover, as Western populations age, this disease is goi...

2018 Collaborative R&D Lead participant

A Technology Platform for Next Generation VNAR Based Oncology Medicines

1 Aug 2018 to 31 Mar 2021

Awarded
£662,847
Total cost £1,325,694

"Despite marked improvements in outcomes for cancer patients, 35% will succumb to the disease. First line chemotherapy treatments generally rely on the sensitivity of fast-growing cancers being more susceptible to toxic agents than ""normal"" healthy cells. The unpleasant side-effects of this treatment, together with a poor prognosis means there is an urg...

Product types

Collaborative R&D Study